FDA Inspection 1117454 — Novocol Pharmaceutical Of Canada, Inc.
The FDA completed an inspection of Novocol Pharmaceutical Of Canada, Inc. on Jan 30, 2020 in Cambridge. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection details
- Classification
- No Action Indicated (NAI)
- End Date
- Jan 30, 2020
- Fiscal Year
- 2020
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Cambridge (Canada)
Additional details
Postmarket Adverse Drug Experience (PADE)